JP2000513348A - 乳腺炎の予防と治療の方法 - Google Patents
乳腺炎の予防と治療の方法Info
- Publication number
- JP2000513348A JP2000513348A JP10502296A JP50229698A JP2000513348A JP 2000513348 A JP2000513348 A JP 2000513348A JP 10502296 A JP10502296 A JP 10502296A JP 50229698 A JP50229698 A JP 50229698A JP 2000513348 A JP2000513348 A JP 2000513348A
- Authority
- JP
- Japan
- Prior art keywords
- microcosin
- milk
- antibiotic
- mastitis
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000004396 mastitis Diseases 0.000 title claims abstract description 37
- 235000013336 milk Nutrition 0.000 claims abstract description 43
- 239000008267 milk Substances 0.000 claims abstract description 43
- 210000004080 milk Anatomy 0.000 claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 230000003115 biocidal effect Effects 0.000 claims abstract description 17
- 235000013351 cheese Nutrition 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 15
- 210000002445 nipple Anatomy 0.000 claims abstract description 15
- 235000013618 yogurt Nutrition 0.000 claims abstract description 15
- 241001465754 Metazoa Species 0.000 claims abstract description 13
- 241000124008 Mammalia Species 0.000 claims abstract description 12
- 238000002347 injection Methods 0.000 claims abstract description 8
- 239000007924 injection Substances 0.000 claims abstract description 8
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 6
- 238000007598 dipping method Methods 0.000 claims abstract description 5
- 241000283690 Bos taurus Species 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 8
- 210000005075 mammary gland Anatomy 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 241000283707 Capra Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 241000192097 Staphylococcus sciuri Species 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 15
- 239000003242 anti bacterial agent Substances 0.000 abstract description 12
- 229940088710 antibiotic agent Drugs 0.000 abstract description 12
- 208000035143 Bacterial infection Diseases 0.000 abstract description 3
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 13
- 239000013543 active substance Substances 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 13
- 241000191967 Staphylococcus aureus Species 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 208000031462 Bovine Mastitis Diseases 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 230000020477 pH reduction Effects 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- MQGFYNRGFWXAKA-GXSYYHJRSA-N Micrococcin Chemical compound C[C@H](O)CNC(=O)C(=C/C)/NC(=O)C1=CSC(C=2N=C(SC=2)C=2N=C3C=4N=C(SC=4)[C@H]([C@@H](C)O)NC(=O)C=4N=C(SC=4)[C@@H](C(C)C)NC(=O)C=4N=C(SC=4)C(=C/C)/NC(=O)[C@H]([C@@H](C)O)NC(=O)C=4N=C(SC=4)C3=CC=2)=N1 MQGFYNRGFWXAKA-GXSYYHJRSA-N 0.000 description 4
- MWGUGTQWSKWBQS-IGHBBLSQSA-N Micrococcin P1 Natural products CC#CC#CC=C1O[C@]2(CC[C@H](O)CO2)[C@@H]3O[C@H]13 MWGUGTQWSKWBQS-IGHBBLSQSA-N 0.000 description 4
- MQGFYNRGFWXAKA-UHFFFAOYSA-N UNPD189813 Natural products CC(O)CNC(=O)C(=CC)NC(=O)C1=CSC(C=2N=C(SC=2)C=2N=C3C=4N=C(SC=4)C(C(C)O)NC(=O)C=4N=C(SC=4)C(C(C)C)NC(=O)C=4N=C(SC=4)C(=CC)NC(=O)C(C(C)O)NC(=O)C=4N=C(SC=4)C3=CC=2)=N1 MQGFYNRGFWXAKA-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 244000144980 herd Species 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- MQGFYNRGFWXAKA-TWSKATCCSA-N micrococcin P1 Natural products CC=C(NC(=O)c1csc(n1)c2csc(n2)c3ccc4c5nc(cs5)C(=O)N[C@@H]([C@@H](C)O)C(=O)NC(=CC)c6nc(cs6)C(=O)N[C@@H](C(C)C)c7nc(cs7)C(=O)N[C@@H]([C@@H](C)O)c8nc(cs8)c4n3)C(=O)NC[C@@H](C)O MQGFYNRGFWXAKA-TWSKATCCSA-N 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 3
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 241000193985 Streptococcus agalactiae Species 0.000 description 3
- 241000194020 Streptococcus thermophilus Species 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000006651 lactation Effects 0.000 description 3
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 210000000712 G cell Anatomy 0.000 description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 244000000015 environmental pathogen Species 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000037125 natural defense Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000001967 plate count agar Substances 0.000 description 2
- -1 polysiloxanes Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QJVHTELASVOWBE-AGNWQMPPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194054 Streptococcus uberis Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- UYRFBMUGEKTBRF-UHFFFAOYSA-M [Mg+].CCCCCCCCCCCCCCCCCC([O-])=O Chemical compound [Mg+].CCCCCCCCCCCCCCCCCC([O-])=O UYRFBMUGEKTBRF-UHFFFAOYSA-M 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013272 agar well diffusion method Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/02—Making cheese curd
- A23C19/05—Treating milk before coagulation; Separating whey from curd
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 治療動物からのミルクを使うチーズ及びヨーグルトの生産を妨げない、哺 乳動物の乳腺炎を治療又は予防する薬を調製するためのミクロコシン抗生物質の 使用 2. 当該抗生物質がミクロコシンP1又はP2である請求項1に記載の使用。 3. 当該薬が乳腺内注射用又は乳首浸漬用である医薬的組成である請求項1に 記載の使用。 4. 請求項1の疎水性ミクロコシン抗生物質の調製のためにスタフィロコッカ ス・シウリ(Staphylococcus sciuri)菌株の使用。 5. 請求項1又は2のいずれかに記載の抗生物質の治療的に有効な量を当該哺 乳動物に投与することを含む、治療動物からのミルクを使うチーズ及びヨーグル トの生産を妨げない哺乳動物の乳腺炎を治療又は予防する方法。 6. 当該抗生物質の連続又は多投与を含む請求項5に記載の方法。 7. 乳腺内注射による又は乳首浸漬による当該抗生物質の投 与を含む請求項5に記載の方法。 8. 当該哺乳動物がウシ、ヤギ又はヒツジである請求項1及び5のいずれかに 記載の方法。 9. 乳腺炎を治療又は予防するためにミクロコシンである疎水性抗生物質の治 療又は予防的用量を受けた哺乳動物からのミルクの出荷停止を回避することがで きる方法。 10. ミクロコシンである疎水性抗生物質により治療された哺乳動物から得た ミルクの使用を含むチーズ及びヨーグルトの生産の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96810415 | 1996-06-20 | ||
EP96810415.8 | 1996-06-20 | ||
PCT/EP1997/003212 WO1997048408A2 (en) | 1996-06-20 | 1997-06-19 | Method for the prevention and treatment of mastitis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000513348A true JP2000513348A (ja) | 2000-10-10 |
JP2000513348A5 JP2000513348A5 (ja) | 2005-02-10 |
Family
ID=8225635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10502296A Ceased JP2000513348A (ja) | 1996-06-20 | 1997-06-19 | 乳腺炎の予防と治療の方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6187800B1 (ja) |
EP (1) | EP0934075B1 (ja) |
JP (1) | JP2000513348A (ja) |
CN (1) | CN1119170C (ja) |
AT (1) | ATE215378T1 (ja) |
AU (1) | AU720243B2 (ja) |
BR (1) | BR9709812A (ja) |
CA (1) | CA2251779A1 (ja) |
DE (1) | DE69711661T2 (ja) |
DK (1) | DK0934075T3 (ja) |
ES (1) | ES2175425T3 (ja) |
IL (1) | IL126489A0 (ja) |
PT (1) | PT934075E (ja) |
WO (1) | WO1997048408A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007534717A (ja) * | 2004-04-29 | 2007-11-29 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 獣医学におけるメロキシカム製剤の使用 |
JP2016507532A (ja) * | 2013-02-08 | 2016-03-10 | ルオダ ファーマ ピーティーワイ リミテッド | 局所微生物感染を処置する方法 |
JP2016507533A (ja) * | 2013-02-08 | 2016-03-10 | ルオダ ファーマ ピーティーワイ リミテッド | 乳房炎をはじめとする微生物感染を処置する方法 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020035107A1 (en) * | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
US6638902B2 (en) * | 2001-02-01 | 2003-10-28 | Ecolab Inc. | Stable solid enzyme compositions and methods employing them |
JP4057426B2 (ja) * | 2001-03-13 | 2008-03-05 | アステラス製薬株式会社 | チオペプタイド化合物 |
DE10161077A1 (de) | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion |
AU2002318711A1 (en) * | 2002-06-28 | 2004-01-19 | Fang Chen | Controllable released suppository used in milk-secreting channel |
US8992980B2 (en) * | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
EP1568369A1 (en) * | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
DE102004030409A1 (de) * | 2004-06-23 | 2006-01-26 | Boehringer Ingelheim Vetmedica Gmbh | Neue Verwendung von Meloxicam in der Veterinärmedizin |
NZ539076A (en) * | 2005-03-29 | 2008-05-30 | Blis Technologies Ltd | Skin treatment compositions |
CN100368016C (zh) * | 2005-04-01 | 2008-02-13 | 北京大北农农业科技研究院 | 治疗奶牛乳房炎的乳房灌注液及其制备方法 |
CA2623201A1 (en) * | 2005-09-30 | 2007-04-12 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical preparation containing meloxicam |
CN100448480C (zh) * | 2005-11-09 | 2009-01-07 | 北京大北农科技集团股份有限公司 | 治疗奶牛乳房炎的乳房用无菌粉针制剂及其制备方法 |
EP2450045A1 (en) * | 2006-10-10 | 2012-05-09 | Wisconsin Alumni Research Foundation | Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses |
CA2757471A1 (en) | 2009-04-08 | 2010-10-14 | Wisconsin Alumni Research Foundation | Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses |
CN102647971B (zh) | 2009-10-12 | 2016-03-16 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 用于包含美洛昔康的组合物的容器 |
EP2361632B1 (en) * | 2010-02-19 | 2014-03-19 | Protectimmun GmbH | Specific environmental bacteria for the protection from and/or the treatment of allergic, chronic inflammatory and/or autoimmune diseases |
US9149480B2 (en) | 2010-03-03 | 2015-10-06 | Boehringer Ingeleheim Vetmedica GmbH | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
TW201607534A (zh) * | 2013-10-31 | 2016-03-01 | 皮拉馬爾企業有限公司 | 治療困難梭狀芽孢桿菌相關感染用硫肽化合物 |
MX2019007633A (es) * | 2016-12-27 | 2019-09-06 | Colgate Palmolive Co | Composicion antitranspirante /desodorante. |
GB202014427D0 (en) * | 2020-09-14 | 2020-10-28 | Norwegian Univ Of Life Sciences | Composition and use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69427492T2 (de) | 1993-08-20 | 2002-04-18 | Novartis Ag | Verfahren zur prävention und behandlung der rindermastitis |
-
1997
- 1997-06-19 DK DK97929226T patent/DK0934075T3/da active
- 1997-06-19 EP EP97929226A patent/EP0934075B1/en not_active Expired - Lifetime
- 1997-06-19 US US09/202,650 patent/US6187800B1/en not_active Expired - Fee Related
- 1997-06-19 PT PT97929226T patent/PT934075E/pt unknown
- 1997-06-19 JP JP10502296A patent/JP2000513348A/ja not_active Ceased
- 1997-06-19 BR BR9709812A patent/BR9709812A/pt not_active Application Discontinuation
- 1997-06-19 CA CA002251779A patent/CA2251779A1/en not_active Abandoned
- 1997-06-19 AU AU33410/97A patent/AU720243B2/en not_active Ceased
- 1997-06-19 CN CN97195584.0A patent/CN1119170C/zh not_active Expired - Fee Related
- 1997-06-19 DE DE69711661T patent/DE69711661T2/de not_active Expired - Fee Related
- 1997-06-19 AT AT97929226T patent/ATE215378T1/de not_active IP Right Cessation
- 1997-06-19 WO PCT/EP1997/003212 patent/WO1997048408A2/en active IP Right Grant
- 1997-06-19 IL IL12648997A patent/IL126489A0/xx unknown
- 1997-06-19 ES ES97929226T patent/ES2175425T3/es not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007534717A (ja) * | 2004-04-29 | 2007-11-29 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 獣医学におけるメロキシカム製剤の使用 |
JP2016507532A (ja) * | 2013-02-08 | 2016-03-10 | ルオダ ファーマ ピーティーワイ リミテッド | 局所微生物感染を処置する方法 |
JP2016507533A (ja) * | 2013-02-08 | 2016-03-10 | ルオダ ファーマ ピーティーワイ リミテッド | 乳房炎をはじめとする微生物感染を処置する方法 |
Also Published As
Publication number | Publication date |
---|---|
DE69711661D1 (de) | 2002-05-08 |
WO1997048408A2 (en) | 1997-12-24 |
ES2175425T3 (es) | 2002-11-16 |
WO1997048408A3 (en) | 1998-02-19 |
CA2251779A1 (en) | 1997-12-24 |
PT934075E (pt) | 2002-08-30 |
US6187800B1 (en) | 2001-02-13 |
DE69711661T2 (de) | 2002-10-17 |
AU720243B2 (en) | 2000-05-25 |
ATE215378T1 (de) | 2002-04-15 |
EP0934075B1 (en) | 2002-04-03 |
CN1119170C (zh) | 2003-08-27 |
BR9709812A (pt) | 1999-08-10 |
CN1222081A (zh) | 1999-07-07 |
AU3341097A (en) | 1998-01-07 |
EP0934075A2 (en) | 1999-08-11 |
IL126489A0 (en) | 1999-08-17 |
DK0934075T3 (da) | 2002-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000513348A (ja) | 乳腺炎の予防と治療の方法 | |
Calvinho et al. | Potential virulence factors of Streptococcus dysgalactiae associated with bovine mastitis | |
Ziv et al. | Tilmicosin antibacterial activity and pharmacokinetics in cows | |
Eberhart | Management of dry cows to reduce mastitis | |
Lacy-Hulbert et al. | Physical characteristics of the bovine teat canal and their influence on susceptibility to streptococcal infection | |
EP0323109B1 (en) | Treatment of mastitis and applicator therefor | |
Ollier et al. | Effects of feed restriction and prolactin-release inhibition at drying-off on susceptibility to new intramammary infection in cows | |
Owens et al. | Efficacy of parenterally or intramammarily administered tilmicosin or ceftiofur against Staphylococcus aureus mastitis during lactation | |
Haritova et al. | Pharmacokinetics of enrofloxacin in lactating sheep | |
McDonald | Streptococcal and staphylococcal mastitis | |
CN111465401A (zh) | 使用人工细菌定殖来预防金黄色葡萄球菌的药物组合物和方法 | |
JP3670280B2 (ja) | ウシの乳房炎の予防および治療方法 | |
JP2004501973A (ja) | 乳房炎の治療および予防のための方法 | |
Klein et al. | Intra‐abdominal versus intramuscular application of two ampicillin preparations in cows | |
Ziv et al. | Clinical pharmacology of cephacetrile in ruminants | |
EP0759077A1 (en) | Lanthionine-containing antimicrobial compound | |
Østerås et al. | The influence of iodine teat dipping and an external teat sealant in heifers on bacterial isolation from quarter milk culture obtained post-calving | |
JP6921805B2 (ja) | ウシ乳腺炎の治療に使用するためのリソバクチン | |
Oliver | Growth of Staphylococcus aureus and Streptococcus species in bovine mammary secretions during the nonlactating and peripartum periods following intramammary infusion of lipopolysaccharide at cessation of milking | |
Owens et al. | The postantibiotic effect of selected antibiotics on Staphylococcus aureus Newbould 305 from bovine intramammary infection | |
Chewulukei | Antibiotic-residues in milk | |
Nickerson et al. | Control of Mastitis and Milk Quality | |
Mahmoud | CONTROL OF SUBCLINICAL MASTITIS IN A BUFFALOE DAIRY HERD USING A FIELD MASTITIES CONTROL PROGRAMME | |
Pradeepkumar | Dry-cow therapy for control of mastitis in cow |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040618 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040618 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070619 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20071107 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080108 |